Market Research

View All

transthyretin amyloidosis
NOTIZIA

British scientists looking forward to treat Alzheimer’s disease through diabetes drug A group of British scientists are looking for the treatment of Alzheimer’s disease in an unlikely source i.e. a drug used for treating Type 2 Diabetes. The team, from Lancaster University, has reported that an experimental three-p...

Find More

Toll-Like Receptor Modulators: Emerging therapy for many indications

Toll-like receptors are a family of various related proteins that play a major role in the development and defense of plants and animals. These receptors were first discovered in Drosophila melanogaster in the late 20th century which later led to the identification of mammalian homologs. Human TLR family consists of...

Find More

EMA to relocate to Amsterdam; Roche’s prospects; Amgen’s Humira Biosimilar delayed; Purdue’s opioid lawsuit

EMA to relocate to Amsterdam by March 2019 Results of the Monday's vote for the European Medicines Agency relocation led to the emergence of Amsterdam as the new headquarters, beating the other finalists Milan and Copenhagen. Nineteen European Union member states submitted proposals for the EMA headquarters, and Mil...

Find More

Notizia
AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes

AstraZeneca and Incyte are about to enter into Clinical Trial Collaboration in Early Lung Cancer The exclusive collaboration for the study population allows the two companies to conduct a Phase 3 trial. Aim of this study is to evaluate patients with locally-advanced (Stage III), unresectable non-small cell lung c...

Find More

PARP Inhibitors making inroads into Ovarian Cancer

Ovarian Cancer is one of the commonly diagnosed cancer among women worldwide. It accounts for nearly 239,000 new cases and 152,000 deaths per year, globally. Treatment landscape of Ovarian Cancer has evolved over the years as the available chemotherapies were not that efficient, giving rise to targeted therapies as ...

Find More

Vitiligo – High Unmet Need Indeed!

Vitiligo is a common acquired, idiopathic depigmentation disorder which affects at least 1% to 2% of the population irrespective of sex, race, or age. The onset of this disease occurs between the ages of 10 and 30.  In this condition, patients progressively lose their skin color, mostly in patches. The patches ...

Find More

Insight on Interstitial Cystitis- The Bladder Pain Syndrome

Interstitial cystitis (IC) is a medical condition that leads to painful bladder syndrome as it is a chronic disease that results in recurring discomfort or pain in the bladder and pelvic region. This condition can be of two types: Non-Ulcerative (90% of IC cases) and Ulcerative (5%-10% of IC cases). The exact cause ...

Find More


Hurry Up! Grab the latest discount offer…

DelveInsight Announces End of the Year Discount on Reports DelveInsight, a Market Research & Business Consulting firm, has announced up to 40% discount offer on its Market Research Reports, starting from 21st November 2016.

Find More

CRISPR gene-editing tested in a person for the first time

  A Chinese group has become the first to inject a person with cells that contain genes edited using the revolutionary CRISPR–Cas9 technique. On 28 October, a team led by oncologist Lu You at Sichuan University in Chengdu delivered the modified cells into a patient with aggressive lung cancer as part of a clinical t...

Find More